Ralph Green
About Ralph E. Green
Independent director of Vivos Therapeutics since June 2020; age 86 as of the 2025 proxy record date. Background spans 35+ years in senior executive roles across dental products and clinical affairs, including implant innovation, clinical trials, and commercialization. Education: DDS (University of Iowa), MBA (Boston University), BA Biology (Graceland University). Board views his qualifications as industry relationships, clinical trials expertise, and executive experience in dental implant and pharmaceutical firms .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Vivos Therapeutics | Independent Director | Jun 2020–present | Audit; Compensation (member) |
| ReachOut Healthcare America (Morgan Stanley PE) | VP, Clinical Affairs | 2003–2017 | Underserved pediatric care focus; clinical oversight |
| Zila Pharmaceuticals, Inc. | President | 1997–2002 | Clinical trials, patents, regulatory submissions |
| Bofors Nobel-Pharma (Nobel Biocare) | U.S. Implant Establishment Lead | Mid-1980s | Launched Swedish Brånemark dental implant in U.S. |
| OTC America | Founder | Late 1980s | Titanium implant surface activation patent; company sold to Collagen |
| Collagen Corporation | Senior Vice President | Post-OTC America acquisition | Post-transaction leadership |
| Biofusion Technology | Founder/Consultant | After Collagen tenure | Consulting in biomaterials |
| Tufts University School of Medicine & Dental Medicine | Assistant Professor | 1970s–1980s | Academic research and teaching |
External Roles
| Organization | Role | Tenure/Recognition | Notes |
|---|---|---|---|
| Dental Manufacturers of America | President-elect and Director | Not specified | Industry body leadership |
| Academy of International Dentistry | Fellow | Honorary | Recognized in Nice, France |
| Marquis Who’s Who in America | Inductee | 2022–2023 | Recognition |
| Private dental practice | President & CEO | 2003–present | Proprietary practice leadership |
Board Governance
- Independence: Affirmatively determined independent (Nasdaq rules) .
- Committees: Audit (member), Compensation (member); no chair roles; not on Nominating & Governance .
- Board leadership: CEO serves as Chair; no Lead Independent Director; independent-only executive sessions held regularly .
- Meetings and attendance:
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Board meetings (count) | 8 | 7 |
| Audit Committee meetings | 6 | 5 |
| Compensation Committee meetings | 4 | 7 |
| Nominating & Governance meetings | 1 | 0 |
| Director attendance rate | 99% | 97% |
| Annual meeting attendance | All directors (Sep 22, 2023) | All directors (Nov 26, 2025) |
- Related-party oversight: Audit Committee pre-approves related party transactions; company disclosed no related-party transactions beyond compensation .
Fixed Compensation
Program structure (non-employee directors): $48,000 annual cash retainer; $10,000 per committee chair; $5,000 per committee membership; no meeting fees; expenses reimbursed .
| Component ($USD) | FY 2023 | FY 2024 |
|---|---|---|
| Annual retainer (cash) | $48,000 | $48,000 |
| Committee membership fees | $10,000 (Audit + Compensation) | $10,000 (Audit + Compensation) |
| Committee chair fees | $0 | $0 |
| Meeting fees | $0 | $0 |
| Total Cash to Ralph E. Green | $58,000 | $58,000 |
Performance Compensation
- Instruments: Stock options; no RSUs/PSUs disclosed for directors.
- Director equity compensation cap: Aggregate annual director cash + equity grant-date fair value capped at $550,000 .
| Equity Metric | FY 2023 | FY 2024 |
|---|---|---|
| Option awards ($ fair value) | $0 | $7,840 |
| RSUs/PSUs (grant details) | Not disclosed | Not disclosed |
| Performance conditions (directors) | Not disclosed | Not disclosed |
Note: Award counts, strike prices, vesting schedules for director grants are not itemized in proxies; company’s omnibus plan permits options, RSUs, SARs, and performance units; dividends on unvested awards prohibited; no repricing without shareholder approval .
Other Directorships & Interlocks
| Company | Role | Committee Roles | Notes |
|---|---|---|---|
| None disclosed (public companies) | — | — | No current public company boards listed for Dr. Green |
Expertise & Qualifications
- Dental implant innovation (pioneered U.S. introduction of Brånemark system; patented titanium surface activation) .
- Executive leadership in pharma/dental firms, clinical affairs oversight, and regulatory submissions .
- Academic and industry body roles (Tufts assistant professor; DMoA leadership; fellow, Academy of International Dentistry) .
- Board views: clinical trials expertise, industry relationships, executive-level experience .
Equity Ownership
| Metric | Value |
|---|---|
| Total beneficial ownership (shares) | 6,400 (all via options exercisable within 60 days) |
| Ownership % of outstanding | <1% |
| Vested/exercisable options | 6,400 within 60 days |
| Unexercisable options | Not disclosed for directors |
| Shares pledged as collateral | Not disclosed |
| Stock ownership guidelines | Not disclosed |
Insider Trades
| Date Range | Form 4 Activity | Notes |
|---|---|---|
| FY 2023–FY 2024 | No delinquent Section 16 filings noted for Ralph E. Green; late filings cited for CEO and CFO (not Green) . | Proxies do not list Green’s individual Form 4 transactions; Section 16 compliance for directors otherwise in order . |
Governance Assessment
- Strengths: Independent status; dual committee membership (Audit and Compensation); robust board-level policies (insider trading windows and pre-clearance; Dodd-Frank-compliant clawback for Covered Executives) .
- Alignment: Modest cash retainers and standardized committee fees; small option grants ($7,840 FY2024) indicating measured equity participation for directors .
- Oversight: No related-party transactions disclosed; Audit Committee reviews related-party and conflict situations; executive sessions of independent directors held .
- Watch items: No Lead Independent Director despite CEO also serving as Chair; Nominating & Governance Committee did not meet in FY2024; director ownership appears entirely via options with no disclosed direct shareholdings, limiting “skin-in-the-game” optics .
Overall signal: Dr. Green’s clinical and industry background supports board effectiveness in a dental/medical device context; independence and committee participation are positives. Governance optics could improve with a lead independent director and more explicit director stock ownership guidelines/holdings to bolster alignment .